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Taking advantage of stress
Inducible heat shock protein 70 (HSP70i) functions in precipitat-
ing vitiligo, an autoimmune disease characterized by destruction 
of melanocytes and lacking effective treatments. Stress-induced 
HSP70i secretion activates dendritic cells (DCs). The presence 
of HSP70i-encoding DNA enhances depigmentation in mice, 
whereas knockout of HSP70i greatly decreases the development 
of progressive depigmentation. Recently, Mosenson and col-
leagues identified a genetic alteration in the DC-binding domain 
of HSP70i (HSP70iQ435A) that interferes with immune activation, 
inhibits depigmentation in vitiligo-prone mice, and prevents 
accumulation of antigen-specific T cells in the skin. The mutant 
HSP70i also interferes with T-cell activation. Importantly, this 
mutant does not activate human DCs in vitro because the altered 
protein binds to DCs and interferes with activation marker expres-
sion. Introduction of the mutant allele into human skin via gene 
gun technology resulted in the alteration of the inflammatory phe-
notype, suggesting the use of this allele as a potential treatment 
for vitiligo. (Sci Transl Med 5:174ra28, 2013) Selected by S. Yuspa
War against hives
The current treatment for chronic idiopathic urticaria involves 
H1-antihistamines; however, a majority of patients fail to 
respond to these drugs. Unfortunately, other agents have not yet 
received regulatory approval for treating urticaria. Recent stud-
ies have described the effectiveness of omalizumab, a recombi-
nant humanized monoclonal antibody that reduces free IgE and 
the high-affinity receptor for the Fc region of IgE, which are both 
essential for pathological mast cell and basophil activation. In an 
international, multicenter, randomized, double-blind, placebo-
controlled study, Maurer and colleagues found that omalizum-
ab administered as three doses at 4-week intervals significantly 
reduced symptoms compared with placebo in patients with 
chronic idiopathic urticaria who remained symptomatic despite 
H1-antihistamine use. Significant and clinically meaningful 
results were documented in patients receiving the higher doses 
of drug. Adverse events were rare but occurred more frequently 
in patients receiving the highest dose. These findings indicate 
that treatment with omalizumab improves outcomes for patients 
with chronic idiopathic urticaria. (N Engl J Med 368:924–35, 
2013) Selected by L. Beck
Copy number of disease
Genetic analysis of systemic lupus erythematosus (SLE) has iden-
tified more than 30 susceptibility loci. Fc-γ receptors have been 
shown to influence SLE susceptibility in rodents, and an associa-
tion between Fcgr3 copy-number variation and SLE in humans 
has been documented. In a recent study, Mueller and colleagues 
examined the FCGR locus on chromosome 1q23 and construct-
ed a detailed map of allelic and paralogous sequence variation. 
In addition to identifying the limits of the breakpoint regions 
association with structural variation at this locus, the investiga-
tors demonstrated that deletion of FCGR3B results in a fusion 
gene that juxtaposes the regulatory region of FCGR2C and the 
coding region of FCGR2B. This fusion protein is ectopically 
expressed in natural killer cells. Together, these results suggest a 
novel explanation for the mechanism underlying the association 
of low FCGR3B copy number and SLE susceptibility. (Am J Hum 
Genet 92:28–40, 2013) Selected by J. Uitto
Histamines at work
Although the pathogenesis of atopic dermatitis (AD) is not 
entirely clear, immunological dysregulation that results in skin 
inflammation and a defective skin barrier are contributing fac-
tors. Mast cells are abundant in lesional skin of AD patients, and 
histamine levels are higher in the skin of AD patients than in the 
skin of healthy individuals. A recent study by Gschwandtner 
and colleagues reported that histamine prevents expression of 
late-differentiation antigens in keratinocytes and impairs epi-
dermal differentiation via activation of the histamine receptor-1. 
Treatment of skin model cultures with histamine resulted in 
keratinocyte differentiation arrest and impaired stratum corne-
um formation. Tight junction and desmosomal junction proteins 
were also downregulated in cells treated with histamines. These 
alterations led to defective skin barrier function in the human 
skin model system. In concert with in vivo observations in mice, 
these findings suggest that histamine may perpetuate a skin bar-
rier defect and that antihistamines may be beneficial for treating 
AD. (Allergy 68:37–47, 2012) Selected by L. Beck
Pour one for me
The polyphenol resveratrol was first identified as a component 
in red wine that provides cardiovascular benefits and antitumor 
activity, and it has since been found to increase life span in 
yeast, worms, and fruit flies. Resveratrol increases mitochondrial 
mass, but whether the NAD+-dependent deacetylase sirtuin 1 
(SIRT1) is involved remains controversial. Price and colleagues 
recently generated an adult-inducible SIRT1-knockout mouse 
and found that moderate doses of resveratrol stimulate AMP-
activated protein kinase (AMPK) activity, increase NAD+ levels, 
induce mitochondrial biogenesis, and increase mitochondrial 
function in skeletal muscle in an SIRT1-dependent manner. 
Indeed, overexpression of SIRT1 mimicked the effects of 
resveratrol. Interestingly, high doses of resveratrol induced 
AMPK activity in a SIRT1-independent manner, but the effects 
on mitochondrial function still required SIRT1. Thus, SIRT1 is 
clearly critical in mediating the benefits of resveratrol in vivo, 
and future exploration of the use of small molecules to mimic 
the effects of resveratrol on SIRT1 activation to treat metabolic 
and age-related diseases is warranted. (Cell Metabolism 
15:675–90, 2012) Selected by B. Gilchrest
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